文献速递乳腺癌放疗放疗物理与技术

乳腺癌放疗后第二原发癌风险:光子与质子技术比较

The risk for developing a secondary cancer after breast radiation therapy: Comparison of photon and proton techniques.
PubMed 文献 · Radiother Oncol · 2020-05-25

该研究基于34例接受全面淋巴结照射的局部晚期乳腺癌患者剂量学数据,利用器官等效剂量模型估算第二原发癌风险。结果显示3DCRT在甲状腺和食管癌风险最低,PBS在肺和对侧乳腺癌风险有优势,VMAT整体风险最高。

要点

  • 3DCRT的甲状腺和食管第二癌风险最低。
  • PBS降低同侧肺和对侧乳腺癌风险。
  • VMAT整体第二原发癌风险最高。

核心结论

  • 3DCRT技术估算的甲状腺和食管第二原发癌风险最低,PBS在第二原发肺癌和对侧乳腺癌风险上显示优势,而VMAT技术总体风险最高。

研究设计与样本

  • 利用34例接受全面淋巴结照射的乳腺癌患者剂量学数据,包括10例光子VMAT、10例光子3DCRT和14例笔束扫描质子(PBS)。
  • 采用基于器官等效剂量的模型估算第二原发癌的超额绝对风险、超额相对风险和终生归因风险(LAR)。

主要发现

  • 70岁时食管癌的LAR最高达3.64%,3DCRT优于PBS和VMAT。
  • 同侧肺癌风险PBS最低(最高5.56%),3DCRT次之(最高6.54%),VMAT最高(最高7.7%)。
  • 对侧肺癌风险3DCRT和PBS明显低于VMAT(风险<0.86% vs 最高4.4%)。
  • 对侧乳腺癌风险3DCRT和PBS可忽略,VMAT最高达1.2%。
  • 甲状腺风险总体可忽略;肉瘤风险趋势相似但总体低于癌。

关键数值与推荐

  • 独立比较治疗计划显示VMAT的对侧肺和对侧乳腺风险可比PBS高一个数量级以上。

临床怎么用

  • 对于局部晚期乳腺癌需全面淋巴结照射的患者,选择质子PBS或3DCRT可降低特定部位第二原发癌风险,应谨慎评估VMAT的使用。

局限性

  • 研究基于剂量学数据和模型估算,非临床结局直接观察。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: To compare secondary malignancy risks of modern proton and photon therapy techniques for locally advanced breast cancer. METHODS AND MATERIALS: We utilized dosimetric data from 34 [10 photon-VMAT, 10 photon-3DCRT, 14 pencil beam scanning proton (PBS)] breast cancer patients who received comprehensive nodal irradiation. Employing a model based on organ equivalent dose to account for both inhomogeneous organ dose distributions and non-linear functional dose relationships, we estimated excess absolute risk, excess relative risk, and lifetime attributable risk (LAR) for secondary malignancies. The model uses dose distribution, number of fractions, age at exposure, attained age, the linear-quadratic dose response relationship for cell survival, repopulation factor, as well as gender specific age dependencies, and initial slopes of dose response curves. RESULTS: The LAR for carcinoma at age 70 was estimated to be up to 3.64% for esophagus with an advantage of 3DCRT over PBS and VMAT. For the ipsilateral lung, risks were lowest for PBS (up to 5.56%), followed by 3DCRT (up to 6.54%) and VMAT (up to 7.7%). For the contralateral lung, there is a clear advantage of 3DCRT and PBS techniques (risk <0.86%) over VMAT (up to 4.4%). The risk for the contralateral breast is negligible for 3DCRT and PBS but was estimated as up to 1.2% for VMAT. Risks for the thyroid are overall negligible. Independently performed comparative treatment plans on 10 patients revealed that the risk for the contralateral lung and breast using VMAT can be more than an order of magnitude higher compared to PBS. Sarcoma risks were estimated as well showing similar trends but were overall lower compared to carcinoma. CONCLUSION: Conventional (3DCRT) techniques led to the lowest estimated risks of, thyroid and esophageal secondary cancers while PBS demonstrated a benefit for secondary lung and contralateral breast cancer risks, with the highest risks overall associated with VMAT techniques.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Paganetti H, Depauw N, Johnson A, et al. The risk for developing a secondary cancer after breast radiation therapy: Comparison of photon and proton techniques. Radiother Oncol. 2020. PMID: 32464163. doi:10.1016/j.radonc.2020.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。